[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, Cinpanemab did not show efficacy in the treatment of Parkinson's Disease. In a 52-week, multicenter, double-blind, phase 2 trial, the change in the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score did not differ significantly between the control group and any of the Cinpanemab groups. The trial was stopped after the week 72 interim analysis due to lack of efficacy. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]